|Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women|
QA Karim, SSA Karim, JA Frohlich, AC Grobler, C Baxter, LE Mansoor, ...
science 329 (5996), 1168-1174, 2010
|Structure and immune recognition of trimeric pre-fusion HIV-1 Env|
M Pancera, T Zhou, A Druz, IS Georgiev, C Soto, J Gorman, J Huang, ...
Nature 514 (7523), 455-461, 2014
|Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies …|
GD Tomaras, NL Yates, P Liu, L Qin, GG Fouda, LL Chavez, AC Decamp, ...
Journal of virology 82 (24), 12449-12463, 2008
|Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies|
NA Doria-Rose, CA Schramm, J Gorman, PL Moore, JN Bhiman, ...
Nature 509 (7498), 55-62, 2014
|Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?|
L Stamatatos, L Morris, DR Burton, JR Mascola
Nature medicine 15 (8), 866-870, 2009
|The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection|
ES Gray, MC Madiga, T Hermanus, PL Moore, CK Wibmer, NL Tumba, ...
Journal of virology 85 (10), 4828-4840, 2011
|Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors|
M Bonsignori, KK Hwang, X Chen, CY Tsao, L Morris, E Gray, DJ Marshall, ...
Journal of virology 85 (19), 9998-10009, 2011
|Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern …|
M Li, JF Salazar-Gonzalez, CA Derdeyn, L Morris, C Williamson, ...
Journal of virology 80 (23), 11776-11790, 2006
|Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C|
JM Binley, EA Lybarger, ET Crooks, MS Seaman, E Gray, KL Davis, ...
Journal of virology 82 (23), 11651-11668, 2008
|Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1|
PL Moore, ET Crooks, L Porter, P Zhu, CS Cayanan, H Grise, P Corcoran, ...
Journal of virology 80 (5), 2515-2528, 2006
|Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection|
ES Gray, PL Moore, IA Choge, JM Decker, F Bibollet-Ruche, H Li, ...
Journal of virology 81 (12), 6187-6196, 2007
|Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration|
R Kantor, DA Katzenstein, B Efron, AP Carvalho, B Wynhoven, P Cane, ...
PLoS Med 2 (4), e112, 2005
|Evolution of an HIV glycan–dependent broadly neutralizing antibody epitope through immune escape|
PL Moore, ES Gray, CK Wibmer, JN Bhiman, M Nonyane, DJ Sheward, ...
Nature medicine 18 (11), 1688-1692, 2012
|Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140|
A Trkola, TJ Ketas, KA Nagashima, L Zhao, T Cilliers, L Morris, JP Moore, ...
Journal of virology 75 (2), 579-588, 2001
|HIV-1 antigen–specific and–nonspecific B cell responses are sensitive to combination antiretroviral therapy|
L Morris, JM Binley, BA Clas, S Bonhoeffer, TP Astill, R Kost, A Hurley, ...
The Journal of experimental medicine 188 (2), 233-245, 1998
|SARS-CoV-2 501Y. V2 escapes neutralization by South African COVID-19 donor plasma|
CK Wibmer, F Ayres, T Hermanus, M Madzivhandila, P Kgagudi, ...
Nature medicine 27 (4), 622-625, 2021
|Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines|
JR Mascola, P D'Souza, P Gilbert, BH Hahn, NL Haigwood, L Morris, ...
Journal of virology 79 (16), 10103-10107, 2005
|Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated|
JA Johnson, J Li, L Morris, N Martinson, G Gray, J McIntyre, W Heneine
The Journal of infectious diseases 192 (1), 16-23, 2005
|Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection|
PL Moore, N Ranchobe, BE Lambson, ES Gray, E Cave, MR Abrahams, ...
PLoS Pathog 5 (9), e1000598, 2009
|Heterozygous mutations of the kinesin KIF21A in congenital fibrosis of the extraocular muscles type 1 (CFEOM1)|
K Yamada, C Andrews, WM Chan, CA McKeown, A Magli, ...
Nature genetics 35 (4), 318-321, 2003